6 June 2024 - Today, the FDA approved imetelstat (Rytelo, Geron Corporation), an oligonucleotide telomerase inhibitor, for adults with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anaemia requiring four or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents.

Efficacy was evaluated in IMerge, a randomised (2:1), double-blind, placebo-controlled multi-centre trial in 178 patients with myelodysplastic syndromes.

Read FDA News